Spironolactone and potassium canrenoate in normal man
- 1 August 1976
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 20 (2), 167-177
- https://doi.org/10.1002/cpt1976202167
Abstract
The pharmacological activity of single doses of the two aldosterone antagonists, potassium canrenoate and spironolactone, was examined in two studies in healthy volunteers. Both drugs were active in reversing urinary electrolyte changes induced by fludrocortisone in periods 2 to 16 hr after treatment. Potassium canrenoate was significantly less potent than spironolactone on a weight or molar basis, with best estimates of the relative potency potassium canrenoate: spironolactone of approximately 0.3 : 1. On a weight basis the two drugs yielded plasma levels of the metabolite canrenone which were approximately equivalent. The results indicate that canrenone is not the principal pharmacologically active metabolite of spironolactone. Our study suggests that a major part of the renal anti mineralocorticoid activity of spironolactone may be attributable to minor sulfur-containing metabolites or their precursors having a high renal clearance that affords access to their site of activity via the renal tubular fluid.This publication has 6 references indexed in Scilit:
- Relationship of Plasma Aldadiene Levels and Antimineralocorticoid Effects of Spironolactone in the LaboratoryExperimental Biology and Medicine, 1964
- PHARMACOLOGICAL PROPERTIES OF MINERALOCORTICOID ANTAGONIST ( SC-14266 )1964
- HUMAN ASSAY OF ELECTROLYTE-ACTIVE STEROIDS AND THEIR ANTAGONISTS1962
- FLUORIMETRIC METHOD FOR DETERMINATION OF A MAJOR SPIRONOLACTONE (ALDACTONE) METABOLITE IN HUMAN PLASMA1962
- BLOCKING THE RENAL ELECTROLYTE EFFECTS OF MINERALOCORTICOIDS WITH AN ORALLY ACTIVE STEROIDAL SPIROLACTONEEndocrinology, 1960
- BIOASSAY OF ADRENAL CORTICAL STEROIDS ON THE BASIS OF ELECTROLYTE EXCRETION BY RATS: EFFECTS OF 11-DESOXY and 11-OXY-STEROIDS1Endocrinology, 1954